Amylin Jumps 12% After Hiring Bankers to Advise on Sale

Shares of Amylin Pharmaceuticals AMLN have surged roughly 12% to $25.76 on Monday after Reuters reported that the company had hired Goldman Aachs GS and Credit Suisse CS to act as its financial advisers in a potential sale. The company also hired Skadden Arps to provide legal advice according to Reuters. The report added that AMLN had reached out to potential buyers in the last week. Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines.